Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Founds clinicians, trained in obesity medicine, can help patients identify the root cause of their weight gain and personalize a prescription to target it
Developer: Eli Lilly and Company | Administration in Trials: Once-weekly subcutaneous injection First successful Phase 3 trial (TRIUMPH-4, topline Dec 2025): Up to 28.7% average body weight loss at 68 weeks (highest dose) in adults with obesity/overweight and knee osteoarthritis
Dulaglutide: Similar to liraglutide at 3-5% average
Moreover, the research also focuses on developing novel GLP-1 analogs, owing to the increased demand
US$ 21.21
US$ 24.53
US$ 25.47
